Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
17
MRKR Quote, Financials, Valuation and Earnings
Last price:
$1.29
Seasonality move
:
-16.83%
Day range:
$1.27 - $1.33
52-week range:
$0.81 - $4.07
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.44x
P/B ratio:
1.31x
Volume:
94K
Avg. volume:
125.8K
1-year change:
10%
Market cap:
$21.7M
Revenue:
$3.5M
EPS (TTM):
-$0.91
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MRKR
Marker Therapeutics, Inc.
|
$682K | -$0.18 | 95.36% | -52.54% | $7.87 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$305.2M | $0.12 | 15.35% | -21.66% | $31.85 |
|
AGEN
Agenus, Inc.
|
$34.5M | -$0.40 | 34.29% | -36.28% | $15.50 |
|
ECOR
electroCore, Inc.
|
$9.7M | -- | 34.11% | -- | $19.80 |
|
TNYA
Tenaya Therapeutics, Inc.
|
$2.5M | -$0.11 | -- | -59.1% | $9.00 |
|
VRDN
Viridian Therapeutics, Inc.
|
$11.6M | -$0.96 | -75.11% | -2.35% | $37.24 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MRKR
Marker Therapeutics, Inc.
|
$1.32 | $7.87 | $21.7M | -- | $0.00 | 0% | 5.44x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$22.20 | $31.85 | $3.8B | 9.65x | $0.00 | 0% | 3.49x |
|
AGEN
Agenus, Inc.
|
$3.33 | $15.50 | $125.6M | -- | $0.00 | 0% | 0.88x |
|
ECOR
electroCore, Inc.
|
$6.80 | $19.80 | $56.4M | -- | $0.00 | 0% | 1.75x |
|
TNYA
Tenaya Therapeutics, Inc.
|
$0.69 | $9.00 | $153.8M | -- | $0.00 | 0% | -- |
|
VRDN
Viridian Therapeutics, Inc.
|
$18.84 | $37.24 | $1.9B | -- | $0.00 | 0% | 22.15x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MRKR
Marker Therapeutics, Inc.
|
-- | 1.671 | -- | 7.49x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 2.895 | 1.15% | 3.40x |
|
AGEN
Agenus, Inc.
|
525.02% | -0.070 | 321.54% | 0.03x |
|
ECOR
electroCore, Inc.
|
122.21% | -0.422 | 26.19% | 1.11x |
|
TNYA
Tenaya Therapeutics, Inc.
|
8.08% | 2.648 | 7.02% | 6.51x |
|
VRDN
Viridian Therapeutics, Inc.
|
6.56% | 2.933 | 1.54% | 12.37x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MRKR
Marker Therapeutics, Inc.
|
-- | -$1.9M | -77.25% | -77.25% | -170.75% | -$1.9M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
AGEN
Agenus, Inc.
|
$33.6M | $14.4M | -3.83% | -- | 42.1% | -$16.6M |
|
ECOR
electroCore, Inc.
|
$7.6M | -$2.9M | -162.38% | -681.93% | -31.82% | -$1.5M |
|
TNYA
Tenaya Therapeutics, Inc.
|
-$1.8M | -$20.8M | -78.2% | -87.41% | -- | -$14M |
|
VRDN
Viridian Therapeutics, Inc.
|
-$188K | -$122.7M | -51.3% | -53.74% | -92991.67% | -$24.5M |
Marker Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns MRKR or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -154.36% compared to Marker Therapeutics, Inc.'s net margin of 96.33%. Marker Therapeutics, Inc.'s return on equity of -77.25% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital MRKRMarker Therapeutics, Inc.-- -$0.10 $16.8M ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About MRKR or ACAD?
Marker Therapeutics, Inc. has a consensus price target of $7.87, signalling upside risk potential of 495.96%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.85 which suggests that it could grow by 43.47%. Given that Marker Therapeutics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Marker Therapeutics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MRKRMarker Therapeutics, Inc.3 0 0 ACADACADIA Pharmaceuticals, Inc.12 4 1 -
Is MRKR or ACAD More Risky?
Marker Therapeutics, Inc. has a beta of 1.471, which suggesting that the stock is 47.131% more volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.833, suggesting its less volatile than the S&P 500 by 16.67%.
-
Which is a Better Dividend Stock MRKR or ACAD?
Marker Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Marker Therapeutics, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRKR or ACAD?
Marker Therapeutics, Inc. quarterly revenues are $1.1M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. Marker Therapeutics, Inc.'s net income of -$1.7M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, Marker Therapeutics, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 9.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Marker Therapeutics, Inc. is 5.44x versus 3.49x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRKRMarker Therapeutics, Inc.5.44x -- $1.1M -$1.7M ACADACADIA Pharmaceuticals, Inc.3.49x 9.65x $284M $273.6M
-
Which has Higher Returns MRKR or AGEN?
Agenus, Inc. has a net margin of -154.36% compared to Marker Therapeutics, Inc.'s net margin of -31.03%. Marker Therapeutics, Inc.'s return on equity of -77.25% beat Agenus, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MRKRMarker Therapeutics, Inc.-- -$0.10 $16.8M AGENAgenus, Inc.98.26% -$0.30 $57M -
What do Analysts Say About MRKR or AGEN?
Marker Therapeutics, Inc. has a consensus price target of $7.87, signalling upside risk potential of 495.96%. On the other hand Agenus, Inc. has an analysts' consensus of $15.50 which suggests that it could grow by 270.37%. Given that Marker Therapeutics, Inc. has higher upside potential than Agenus, Inc., analysts believe Marker Therapeutics, Inc. is more attractive than Agenus, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MRKRMarker Therapeutics, Inc.3 0 0 AGENAgenus, Inc.2 0 0 -
Is MRKR or AGEN More Risky?
Marker Therapeutics, Inc. has a beta of 1.471, which suggesting that the stock is 47.131% more volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.604, suggesting its more volatile than the S&P 500 by 60.406%.
-
Which is a Better Dividend Stock MRKR or AGEN?
Marker Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Marker Therapeutics, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRKR or AGEN?
Marker Therapeutics, Inc. quarterly revenues are $1.1M, which are smaller than Agenus, Inc. quarterly revenues of $34.2M. Marker Therapeutics, Inc.'s net income of -$1.7M is higher than Agenus, Inc.'s net income of -$10.6M. Notably, Marker Therapeutics, Inc.'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Marker Therapeutics, Inc. is 5.44x versus 0.88x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRKRMarker Therapeutics, Inc.5.44x -- $1.1M -$1.7M AGENAgenus, Inc.0.88x -- $34.2M -$10.6M
-
Which has Higher Returns MRKR or ECOR?
electroCore, Inc. has a net margin of -154.36% compared to Marker Therapeutics, Inc.'s net margin of -32.84%. Marker Therapeutics, Inc.'s return on equity of -77.25% beat electroCore, Inc.'s return on equity of -681.93%.
Company Gross Margin Earnings Per Share Invested Capital MRKRMarker Therapeutics, Inc.-- -$0.10 $16.8M ECORelectroCore, Inc.82.07% -$0.38 $7.7M -
What do Analysts Say About MRKR or ECOR?
Marker Therapeutics, Inc. has a consensus price target of $7.87, signalling upside risk potential of 495.96%. On the other hand electroCore, Inc. has an analysts' consensus of $19.80 which suggests that it could grow by 191.18%. Given that Marker Therapeutics, Inc. has higher upside potential than electroCore, Inc., analysts believe Marker Therapeutics, Inc. is more attractive than electroCore, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MRKRMarker Therapeutics, Inc.3 0 0 ECORelectroCore, Inc.4 0 0 -
Is MRKR or ECOR More Risky?
Marker Therapeutics, Inc. has a beta of 1.471, which suggesting that the stock is 47.131% more volatile than S&P 500. In comparison electroCore, Inc. has a beta of 0.590, suggesting its less volatile than the S&P 500 by 40.952%.
-
Which is a Better Dividend Stock MRKR or ECOR?
Marker Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. electroCore, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Marker Therapeutics, Inc. pays -- of its earnings as a dividend. electroCore, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRKR or ECOR?
Marker Therapeutics, Inc. quarterly revenues are $1.1M, which are smaller than electroCore, Inc. quarterly revenues of $9.2M. Marker Therapeutics, Inc.'s net income of -$1.7M is higher than electroCore, Inc.'s net income of -$3M. Notably, Marker Therapeutics, Inc.'s price-to-earnings ratio is -- while electroCore, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Marker Therapeutics, Inc. is 5.44x versus 1.75x for electroCore, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRKRMarker Therapeutics, Inc.5.44x -- $1.1M -$1.7M ECORelectroCore, Inc.1.75x -- $9.2M -$3M
-
Which has Higher Returns MRKR or TNYA?
Tenaya Therapeutics, Inc. has a net margin of -154.36% compared to Marker Therapeutics, Inc.'s net margin of --. Marker Therapeutics, Inc.'s return on equity of -77.25% beat Tenaya Therapeutics, Inc.'s return on equity of -87.41%.
Company Gross Margin Earnings Per Share Invested Capital MRKRMarker Therapeutics, Inc.-- -$0.10 $16.8M TNYATenaya Therapeutics, Inc.-- -$0.12 $134.1M -
What do Analysts Say About MRKR or TNYA?
Marker Therapeutics, Inc. has a consensus price target of $7.87, signalling upside risk potential of 495.96%. On the other hand Tenaya Therapeutics, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 1195.71%. Given that Tenaya Therapeutics, Inc. has higher upside potential than Marker Therapeutics, Inc., analysts believe Tenaya Therapeutics, Inc. is more attractive than Marker Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MRKRMarker Therapeutics, Inc.3 0 0 TNYATenaya Therapeutics, Inc.6 0 0 -
Is MRKR or TNYA More Risky?
Marker Therapeutics, Inc. has a beta of 1.471, which suggesting that the stock is 47.131% more volatile than S&P 500. In comparison Tenaya Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock MRKR or TNYA?
Marker Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tenaya Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Marker Therapeutics, Inc. pays -- of its earnings as a dividend. Tenaya Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRKR or TNYA?
Marker Therapeutics, Inc. quarterly revenues are $1.1M, which are larger than Tenaya Therapeutics, Inc. quarterly revenues of --. Marker Therapeutics, Inc.'s net income of -$1.7M is higher than Tenaya Therapeutics, Inc.'s net income of -$20.2M. Notably, Marker Therapeutics, Inc.'s price-to-earnings ratio is -- while Tenaya Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Marker Therapeutics, Inc. is 5.44x versus -- for Tenaya Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRKRMarker Therapeutics, Inc.5.44x -- $1.1M -$1.7M TNYATenaya Therapeutics, Inc.-- -- -- -$20.2M
-
Which has Higher Returns MRKR or VRDN?
Viridian Therapeutics, Inc. has a net margin of -154.36% compared to Marker Therapeutics, Inc.'s net margin of -77256.06%. Marker Therapeutics, Inc.'s return on equity of -77.25% beat Viridian Therapeutics, Inc.'s return on equity of -53.74%.
Company Gross Margin Earnings Per Share Invested Capital MRKRMarker Therapeutics, Inc.-- -$0.10 $16.8M VRDNViridian Therapeutics, Inc.-142.42% -$1.08 $772.9M -
What do Analysts Say About MRKR or VRDN?
Marker Therapeutics, Inc. has a consensus price target of $7.87, signalling upside risk potential of 495.96%. On the other hand Viridian Therapeutics, Inc. has an analysts' consensus of $37.24 which suggests that it could grow by 97.64%. Given that Marker Therapeutics, Inc. has higher upside potential than Viridian Therapeutics, Inc., analysts believe Marker Therapeutics, Inc. is more attractive than Viridian Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MRKRMarker Therapeutics, Inc.3 0 0 VRDNViridian Therapeutics, Inc.14 1 0 -
Is MRKR or VRDN More Risky?
Marker Therapeutics, Inc. has a beta of 1.471, which suggesting that the stock is 47.131% more volatile than S&P 500. In comparison Viridian Therapeutics, Inc. has a beta of 1.166, suggesting its more volatile than the S&P 500 by 16.64%.
-
Which is a Better Dividend Stock MRKR or VRDN?
Marker Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viridian Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Marker Therapeutics, Inc. pays -- of its earnings as a dividend. Viridian Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRKR or VRDN?
Marker Therapeutics, Inc. quarterly revenues are $1.1M, which are larger than Viridian Therapeutics, Inc. quarterly revenues of $132K. Marker Therapeutics, Inc.'s net income of -$1.7M is higher than Viridian Therapeutics, Inc.'s net income of -$102M. Notably, Marker Therapeutics, Inc.'s price-to-earnings ratio is -- while Viridian Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Marker Therapeutics, Inc. is 5.44x versus 22.15x for Viridian Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRKRMarker Therapeutics, Inc.5.44x -- $1.1M -$1.7M VRDNViridian Therapeutics, Inc.22.15x -- $132K -$102M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 5
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 5
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 5
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
